NEKTAR THERAPEUTICS 8-K

What Happened

• Nektar Therapeutics announced its financial results for the quarter ended December 31, 2025, via a press release dated March 12, 2026. The press release is furnished as Exhibit 99.1 to the Form 8-K titled “Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results.”
• The company stated the information in the 8-K and exhibit is being furnished (not “filed”) and therefore is not subject to Section 18 liability or to incorporation by reference into other SEC filings.

Key Details

• Date of disclosure: March 12, 2026.
• Reporting period: Quarter ended December 31, 2025 (fourth quarter) and full year 2025.
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• The filing includes the Inline XBRL cover page (Exhibit 104).

Why It Matters

• The announcement contains Nektar’s latest quarterly and annual earnings and other financial metrics investors watch (earnings, revenue, quarterly results). Investors should read the press release for the specific numbers and any management commentary on performance or outlook.
• Because the release is furnished rather than filed, it’s provided for investor information but isn’t subject to the liability protections and incorporation rules that apply to “filed” disclosures. This affects how the information can be used in later SEC filings.